ACHL (Achilles Therapeutics) LT-Debt-to-Total-Asset : 0.00 (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Achilles Therapeutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Achilles Therapeutics's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.00.

Achilles Therapeutics's long-term debt to total assets ratio declined from Sep. 2023 (0.02) to Sep. 2024 (0.00). It may suggest that Achilles Therapeutics is progressively becoming less dependent on debt to grow their business.

Achilles Therapeutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Achilles Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achilles Therapeutics LT-Debt-to-Total-Asset Chart

Achilles Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

0.06

0.03

0.02

0.01

Achilles Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.02	0.01	-	-	-

Achilles Therapeutics LT-Debt-to-Total-Asset Calculation

Achilles Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	1.076	/	161.456
	=

Achilles Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	0	/	122.676
	=

Achilles Therapeutics (NAS:ACHL) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Achilles Therapeutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Achilles Therapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Achilles Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achilles Therapeutics PLC (NAS:ACHL) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

698:Germany

Address

245 Hammersmith Road, London, GBR, W6 8PW

Website

https://www.achillestx.com

Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.